Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7253205 | 0.89 | IGF1R (0.80) | IGF1RALDH1A1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL14195910 | 0.89 | IGF1R (0.80) | IGF1RALDH1A1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL4494376 | 0.88 | IGF1R (0.79) | IGF1RALDH1A1KMT2APOLBMAPK1 | |
| SCHEMBL4208158 | 0.86 | IGF1R (0.76) | IGF1RALDH1A1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL3131054 | 0.86 | ALDH1A1 (0.78) | IGF1RALDH1A1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL13919302 | 0.86 | IGF1R (0.76) | IGF1RALDH1A1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL7122759 | 0.86 | IGF1R (0.76) | IGF1RALDH1A1SMN1; SMN2MAPK1HPGD | |
| SCHEMBL7114812 | 0.85 | IGF1R (0.73) | IGF1RALDH1A1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL4205450 | 0.84 | IGF1R (0.71) | IGF1RALDH1A1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL7122223 | 0.83 | IGF1R (0.71) | IGF1RALDH1A1KMT2APOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003035616-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-05-01 | — | — | WO | claimed |
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | MERCK SHARP & DOHME (US) | 2015-04-02 | — | — | US | disclosed |
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | MERCK SHARP & DOHME (US) | 2015-04-02 | — | — | US | disclosed |
| US-20120058112-A1 | ANTIBODIES | MERCK SHARP & DOHME CORP. | 2012-03-08 | — | — | US | disclosed |
| US-20120058112-A1 | ANTIBODIES | MERCK SHARP & DOHME CORP. | 2012-03-08 | — | — | US | disclosed |
| US-20110262525-A1 | METHODS OF TREATMENT | SCHERING CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110262525-A1 | METHODS OF TREATMENT | SCHERING CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2003035616-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058112-A1 | ANTIBODIES | IGF1R, EGFR, ERBB3 | IGF1R 1/4885ALDH1A1 1627/4885KMT2A 576/4885 |
| US-20110262525-A1 | METHODS OF TREATMENT | ASAH2, FOLH1, CD44 | IGF1R 2978/4885ALDH1A1 1200/4885KMT2A 2834/4885 |
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | BRCA1, VHL, TP53 | IGF1R 4709/4885ALDH1A1 484/4885KMT2A 2332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.